No Data
No Data
Cantor Fitzgerald Initiates Protara Therapeutics(TARA.US) With Buy Rating
Protara Therapeutics Initiated at Overweight by Cantor Fitzgerald
LifeSci Capital Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $22
LifeSci Capital Initiates Coverage On Protara Therapeutics With Outperform Rating, Announces Price Target of $22
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $30
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $23